191 related articles for article (PubMed ID: 8228235)
41. Mycobacterium avium infection in BALB/c and SCID mice.
Fattorini L; Mattei M; Placido R; Li BO; Iona E; Agrimi U; Colizzi V; Orefici G
J Med Microbiol; 1999 Jun; 48(6):577-583. PubMed ID: 10359307
[TBL] [Abstract][Full Text] [Related]
42. IL-32 expression in the airway epithelial cells of patients with Mycobacterium avium complex lung disease.
Bai X; Ovrutsky AR; Kartalija M; Chmura K; Kamali A; Honda JR; Oberley-Deegan RE; Dinarello CA; Crapo JD; Chang LY; Chan ED
Int Immunol; 2011 Nov; 23(11):679-91. PubMed ID: 22033195
[TBL] [Abstract][Full Text] [Related]
43. Endogenous interleukin 10 prevents apoptosis in macrophages during Salmonella infection.
Arai T; Hiromatsu K; Nishimura H; Kimura Y; Kobayashi N; Ishida H; Nimura Y; Yoshikai Y
Biochem Biophys Res Commun; 1995 Aug; 213(2):600-7. PubMed ID: 7646518
[TBL] [Abstract][Full Text] [Related]
44. Blocking the receptor for IL-10 improves antimycobacterial chemotherapy and vaccination.
Silva RA; Pais TF; Appelberg R
J Immunol; 2001 Aug; 167(3):1535-41. PubMed ID: 11466374
[TBL] [Abstract][Full Text] [Related]
45. Interleukin-2 and loss of immunity in experimental Mycobacterium avium infection.
Mannering SI; Cheers C
Infect Immun; 2002 Jan; 70(1):27-35. PubMed ID: 11748160
[TBL] [Abstract][Full Text] [Related]
46. Maximum growth rate of Mycobacterium avium in continuous culture or chronically infected BALB/c mice.
McCarthy CM; Taylor MA; Dennis MW
Microbios; 1987; 52(211):97-103. PubMed ID: 3695991
[TBL] [Abstract][Full Text] [Related]
47. [Development of experimental model animals for disseminated Mycobacterium avium complex infections using immunodeficient mice and rats].
Emori M; Saito H; Tomioka H; Setogawa T
Kekkaku; 1994 Apr; 69(4):317-22. PubMed ID: 8189685
[TBL] [Abstract][Full Text] [Related]
48. Interleukin-6 antagonizes tumor necrosis factor-mediated mycobacteriostatic and mycobactericidal activities in macrophages.
Bermudez LE; Wu M; Petrofsky M; Young LS
Infect Immun; 1992 Oct; 60(10):4245-52. PubMed ID: 1328056
[TBL] [Abstract][Full Text] [Related]
49. Effects of the Chinese traditional medicine mao-bushi-saishin-to on therapeutic efficacy of a new benzoxazinorifamycin, KRM-1648, against Mycobacterium avium infection in mice.
Shimizu T; Tomioka H; Sato K; Sano C; Akaki T; Dekio S; Yamada Y; Kamei T; Shibata H; Higashi N
Antimicrob Agents Chemother; 1999 Mar; 43(3):514-9. PubMed ID: 10049260
[TBL] [Abstract][Full Text] [Related]
50. Exposure of BALB/c mice to low doses of Mycobacterium avium increases resistance to a subsequent high-dose infection.
Fattorini L; Nisini R; Fan Y; Li YJ; Tan D; Mariotti S; Teloni R; Iona E; Orefici G
Microbiology (Reading); 2002 Oct; 148(Pt 10):3173-3181. PubMed ID: 12368451
[TBL] [Abstract][Full Text] [Related]
51. Generalized immunological decline during long-term experimental infection with Mycobacterium avium.
Gilbertson B; Cheers C
Infect Immun; 2002 Dec; 70(12):7145-8. PubMed ID: 12438398
[TBL] [Abstract][Full Text] [Related]
52. Late acquisition of hyporesponsiveness to lipopolysaccharide by Mycobacterium avium-infected human macrophages in producing tumor necrosis factor-alpha but not interleukin-1 beta and -6.
Fattorini L; Xiao Y; Ausiello CM; Urbani F; laSala A; Mattei M; Orefici G
J Infect Dis; 1996 Apr; 173(4):1030-4. PubMed ID: 8603946
[TBL] [Abstract][Full Text] [Related]
53. Antiphospholipid IgM antibody response in acute and chronic Mycobacterium tuberculosis mouse infection model.
Goodridge A; Zhang T; Miyata T; Lu S; Riley LW
Clin Respir J; 2014 Apr; 8(2):137-44. PubMed ID: 23910993
[TBL] [Abstract][Full Text] [Related]
54. [Effects of various steroidal and non-steroidal anti-inflammatory drugs on in-vitro IL-10 production of murine peritoneal macrophages infected with Mycobacterium avium complex].
Shimizu T; Sano C; Sato K; Tomioka H
Kansenshogaku Zasshi; 1997 Sep; 71(9):910-7. PubMed ID: 9339628
[TBL] [Abstract][Full Text] [Related]
55. Control of Mycobacterium fortuitum and Mycobacterium intracellulare infections with respect to distinct granuloma formations in livers of BALB/c mice.
Silva TR; Petersen AL; Santos Tde A; Almeida TF; Freitas LA; Veras PS
Mem Inst Oswaldo Cruz; 2010 Aug; 105(5):642-8. PubMed ID: 20835610
[TBL] [Abstract][Full Text] [Related]
56. Interleukin-6 production during chronic experimental infection.
Saunders BM; Liu Z; Zhan Y; Cheers C
Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():275-80. PubMed ID: 8225396
[TBL] [Abstract][Full Text] [Related]
57. Natural killer cell-dependent mycobacteriostatic and mycobactericidal activity in human macrophages.
Bermudez LE; Young LS
J Immunol; 1991 Jan; 146(1):265-70. PubMed ID: 1898601
[TBL] [Abstract][Full Text] [Related]
58. Endogenous inhibition of antimycobacterial immunity by IL-10 varies between mycobacterial species.
Roach DR; Martin E; Bean AG; Rennick DM; Briscoe H; Britton WJ
Scand J Immunol; 2001; 54(1-2):163-70. PubMed ID: 11439163
[TBL] [Abstract][Full Text] [Related]
59. IL-10 underlies distinct susceptibility of BALB/c and C57BL/6 mice to Mycobacterium avium infection and influences efficacy of antibiotic therapy.
Roque S; Nobrega C; Appelberg R; Correia-Neves M
J Immunol; 2007 Jun; 178(12):8028-35. PubMed ID: 17548640
[TBL] [Abstract][Full Text] [Related]
60. Modulation of Mycobacterium avium growth in murine macrophages: reversal of unresponsiveness to interferon-gamma by indomethacin or interleukin-4.
Denis M; Gregg EO
J Leukoc Biol; 1991 Jan; 49(1):65-72. PubMed ID: 1898613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
